Cara Therapeutics, Inc. (NASDAQ:CARA)‘s stock had its “buy” rating reiterated by equities researchers at Stifel Nicolaus in a note issued to investors on Friday.

CARA has been the subject of several other reports. Raymond James Financial, Inc. reiterated a “market perform” rating and issued a $30.00 target price on shares of Cara Therapeutics in a report on Friday, April 28th. Piper Jaffray Companies reiterated an “overweight” rating and issued a $23.00 target price on shares of Cara Therapeutics in a report on Friday, March 3rd. HC Wainwright upped their target price on Cara Therapeutics from $22.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday, March 28th. Zacks Investment Research cut Cara Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, March 14th. Finally, Vetr upgraded Cara Therapeutics from a “hold” rating to a “buy” rating and set a $18.44 target price for the company in a report on Wednesday, April 5th. Three analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $26.30.

Analyst Recommendations for Cara Therapeutics (NASDAQ:CARA)

Shares of Cara Therapeutics (NASDAQ:CARA) opened at 22.65 on Friday. The company has a 50-day moving average price of $16.70 and a 200-day moving average price of $14.92. Cara Therapeutics has a 52 week low of $4.35 and a 52 week high of $23.55. The stock’s market cap is $736.28 million. Cara Therapeutics also was the target of unusually large options trading on Friday. Stock investors acquired 395 put options on the stock. This represents an increase of 150% compared to the typical volume of 158 put options.

Cara Therapeutics (NASDAQ:CARA) last issued its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.73) by $0.08. The business had revenue of $0.91 million during the quarter, compared to analyst estimates of $0.11 million. During the same period last year, the company earned ($0.39) EPS. The company’s revenue for the quarter was up 12900.0% on a year-over-year basis. Equities analysts anticipate that Cara Therapeutics will post ($2.37) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This report was first reported by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another site, it was stolen and reposted in violation of international copyright & trademark law. The original version of this report can be read at https://www.americanbankingnews.com/2017/06/24/cara-therapeutics-inc-cara-given-buy-rating-at-stifel-nicolaus.html.

In related news, major shareholder Ventures Vi Lp Rho acquired 500,000 shares of the firm’s stock in a transaction that occurred on Friday, March 31st. The stock was purchased at an average cost of $18.19 per share, for a total transaction of $9,095,000.00. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 7.70% of the company’s stock.

Large investors have recently modified their holdings of the company. Wells Fargo & Company MN boosted its stake in shares of Cara Therapeutics by 127.2% in the third quarter. Wells Fargo & Company MN now owns 12,007 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 6,722 shares during the period. Jacobs Levy Equity Management Inc. bought a new stake in shares of Cara Therapeutics during the first quarter worth $112,000. Private Advisor Group LLC bought a new stake in shares of Cara Therapeutics during the fourth quarter worth $117,000. Quantbot Technologies LP bought a new stake in shares of Cara Therapeutics during the first quarter worth $124,000. Finally, Flinton Capital Management LLC bought a new stake in shares of Cara Therapeutics during the fourth quarter worth $139,000. Hedge funds and other institutional investors own 52.91% of the company’s stock.

About Cara Therapeutics

Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body’s peripheral nervous system.

Receive News & Ratings for Cara Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.